Pharmacokinetics Studies: Market Size & Forecast 2026

The global pharmacokinetics studies market sits at approximately USD 1.45 billion in 2025 (base year), anchored by a structurally defensive demand profile across small-molecule generic bioequivalence, innovator Phase I programmes, and a growing biologics immunogenicity tail. Clinical site and bioanalytical laboratory costs together account for roughly 64 percent of delivered cost, making these the two levers buyers can most directly influence through structuring and sourcing choices. The market grows at a 6.8 percent CAGR through 2032, with Phase I clinical PK studies (including SAD/MAD and BE/BA work) representing the single largest segment at 38 percent of revenue, while preclinical ADME/PK holds 32 percent and population PK/PBPK modelling the fastest-growing niche at 14 percent with a estimated CAGR north of 9 percent. > **Analyst Take.** Our view: the consensus 6.8 percent CAGR is ac

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.